Bayer to buy BIVI’s Cydectin parasiticides

December 13, 2016

Boehringer Ingelheim Vetmedica Inc. continues to shed assets as it finalizes a merger with veterinary drug maker Merial Ltd.

Bayer Animal Health of Shawnee, Kan., will acquire BIVI’s Cydectin (moxidectin) line, which is formulated to control parasites in cattle and sheep, the companies announced Dec. 7. The transaction, which covers U.S. sales of Cydectin, is expected to close in the first quarter of 2017 and is necessary to satisfy regulatory requirements as the Merial merger[1] nears.

BIVI in October sold more than 40 feline, canine and rabies vaccines to Elanco Animal Health[2] for $885 million. The value of the Cydectin deal was not reported.

“The U.S. is our most important market, and the addition of the Cydectin products will help further strengthen our position in cattle parasiticides in the U.S.,” said Dirk Ehle, who leads Bayer Animal Health.

The Cydectin line is made up of:

BIVI’s North American headquarters is in St. Joseph. Mo. The merged company will be based in Merial’s hometown of Duluth, Ga.

Endnotes:
  1. Merial merger: http://www.veterinarypracticenews.com/veterinary-drug-makers-merial-boehringer-plan-merger/
  2. Elanco Animal Health: http://www.veterinarypracticenews.com/boehringer-to-sell-vaccine-lines-to-elanco/

Source URL: https://www.veterinarypracticenews.com/bayer-to-buy-bivis-cydectin-parasiticides/